21,872 Shares in Tango Therapeutics, Inc. $TNGX Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,872 shares of the company’s stock, valued at approximately $195,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd lifted its position in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares during the period. Legal & General Group Plc raised its position in shares of Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tango Therapeutics by 148,800.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Tango Therapeutics by 44.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,473 shares of the company’s stock valued at $49,000 after acquiring an additional 2,907 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new position in Tango Therapeutics in the 2nd quarter valued at $51,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on TNGX. Guggenheim boosted their price target on Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, March 6th. Wall Street Zen cut shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Piper Sandler boosted their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. B. Riley Financial reissued a “buy” rating on shares of Tango Therapeutics in a research note on Friday, March 27th. Finally, Wedbush boosted their price objective on shares of Tango Therapeutics from $15.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.44.

Tango Therapeutics Trading Up 8.6%

Shares of Tango Therapeutics stock opened at $25.51 on Thursday. The company has a fifty day moving average price of $21.14 and a 200 day moving average price of $14.07. The stock has a market cap of $3.68 billion, a price-to-earnings ratio of -29.32 and a beta of 1.22. Tango Therapeutics, Inc. has a twelve month low of $1.25 and a twelve month high of $28.41.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.32). Tango Therapeutics had a negative net margin of 151.15% and a negative return on equity of 50.30%. Analysts forecast that Tango Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Insider Activity

In other news, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $21.23, for a total value of $573,210.00. Following the sale, the insider owned 115,743 shares in the company, valued at approximately $2,457,223.89. This represents a 18.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have sold 179,056 shares of company stock valued at $3,346,181. Corporate insiders own 6.50% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.